Mammogen to Showcase New Data at SABCS 2023 Demonstrating Clinical Efficacy of Its genTRU-breast™ qPCR Blood Test in Early-Stage Breast Cancer
Txylo.com/10258598

NEWPORT BEACH, Calif., Dec. 1, 2023 ~ Mammogen, a subsidiary of early detection parent company IVBH, is set to present groundbreaking clinical data at the 2023 San Antonio Breast Cancer Symposium (SABCS). The poster, titled "Development of a plasma-based real-time qPCR gene expression assay for targeted screening and diagnosis of early-stage breast cancer," will showcase the strength and innovation of Mammogen's proprietary genTRU-breast clinical assay.

This follows Mammogen's successful CLIA validation of the genTRU-breast assay, announced last month. This was a landmark achievement for the company and a transformative milestone in early-stage breast cancer detection.

More on Txylo.com

• Operation Lone Star Arrest Drug, Human Smugglers In Texas
• CCHR Seeks Redress for Those Forcibly Held and Harmed in Behavioral Facilities
• Governor Abbott Announces Rockwall Designated Music Friendly Texas Certified Community
• DocVilla Introduces Best All-in-One Customizable Cloud-Based EHR Practice Management Software for Multi-Specialty and Small Practices
• SEI Announces Kelly O'Rourke as New Managing Director of Dallas Office

The data presented at SABCS will demonstrate the statistically significant >99% sensitivity and 89% specificity in stage I breast cancer achieved during CLIA validation. This reinforces Mammogen's position as a leader in accurate, affordable, scalable, and socially responsible diagnostics in women's health.

Elizabeth Cormier-May, CEO of Mammogen commented on this achievement saying "This data is a testament to our commitment to unlocking the quality-of-life preservation that exists in the earliest stages of breast cancer."

The poster session will take place on Wednesday December 6th at 12:00 PM - 2:00 PM at Henry B. Gonzalez Convention Center in San Antonio, Texas.

---

Show All News | Report Violation